🇺🇸 FDA
Patent

US 8609395

Agonist and antagonist peptides of carcinoembryonic antigen (CEA)

granted A61KA61K38/00A61K39/00

Quick answer

US patent 8609395 (Agonist and antagonist peptides of carcinoembryonic antigen (CEA)) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Dec 12 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Dec 17 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 12 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61K, A61K38/00, A61K39/00, A61K48/00, A61P